Class not certified for abstract (“what if?”) harm respecting increased risk of cancer diagnosis: Palmer v. Teva Canada Ltd., 2022 ONSC 4690 | Alexander Holburn Beaudin + Lang LLP
Teva introduces ProAir Digihaler inhalation powder for asthma and COPD
Teva Canada Announces Product Availability of AJOVY™ | Nasdaq
Teva Canada Recalls Advanced Relief Eye Drops Due To Packaging Error - Top Class Actions Canada
Teva Canada Announces the Launch of AJOVY™ For the Preventive Treatment of Migraine in Adults Who Have at Least Four Migraine Days Per Month | Business Wire
Teva Original Universal Sandals for Women
Teva (TEVA) Stock Is Still Facing Major Risk at This Point | InvestorPlace
Teva follows AbbVie to leave top pharma industry group (NYSE:TEVA) | Seeking Alpha
Teva Canada announces availability of Aermony RespiClick™, an innovative new device for the treatment of bronchial asthma